| Entry |
|
|---|
| Name |
Ertugliflozin pidolate;
Ertugliflozin L-pyroglutamic acid;
Steglatro (TN) |
|---|
| Product |
|
|---|
| Formula |
C22H25ClO7. C5H7NO3
|
|---|
| Exact mass |
565.1715
|
|---|
| Mol weight |
565.9967
|
|---|
| Structure |
|
|---|
| Class |
|
|---|
| Remark |
| Product (DG02836): | D11043<US> |
| Product (mixture): | D11066<US> D11067<US> |
|
|---|
| Efficacy |
Antidiabetic, SGLT-2 inhibitor |
|---|
| Disease |
Type 2 diabetes mellitus [DS: H00409] |
|---|
| Target |
|
|---|
| Metabolism |
Enzyme: UGT1A9 [HSA: 54600], UGT2B7 [HSA: 7364]
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A10 DRUGS USED IN DIABETES
A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10BK Sodium-glucose co-transporter 2 (SGLT2) inhibitors
A10BK04 Ertugliflozin
D11043 Ertugliflozin pidolate <US>
USP drug classification [BR:br08302]
Blood Glucose Regulators
Antidiabetic Agents
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhbitor
Ertugliflozin
D11043 Ertugliflozin pidolate
Cardiovascular Agents
Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i)
Ertugliflozin
D11043 Ertugliflozin pidolate
Drug groups [BR:br08330]
Antidiabetic agent
DG02044 Hypoglycemic agent
DG01794 SGLT2 inhibitor
DG02836 Ertugliflozin
D11043 Ertugliflozin pidolate
Metabolizing enzyme substrate
DG02924 UGT substrate
DG03188 UGT1A9 substrate
DG02836 Ertugliflozin
D11043 Ertugliflozin pidolate
DG03190 UGT2B7 substrate
DG02836 Ertugliflozin
D11043 Ertugliflozin pidolate
Drug classes [BR:br08332]
Antidiabetic agent
DG01794 SGLT2 inhibitor
D11043 Ertugliflozin pidolate
DG02044 Hypoglycemic agent
D11043 Ertugliflozin pidolate
Target-based classification of drugs [BR:br08310]
Transporters
Solute carrier family
SLC5
SLC5A2 (SGLT2)
D11043 Ertugliflozin pidolate <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11043
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11043
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11043
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D11043
Drug groups [BR:br08330]
Antidiabetic agent
DG02044 Hypoglycemic agent
DG01794 SGLT2 inhibitor
DG02836 Ertugliflozin
Metabolizing enzyme substrate
DG02924 UGT substrate
DG03188 UGT1A9 substrate
DG02836 Ertugliflozin
DG03190 UGT2B7 substrate
DG02836 Ertugliflozin
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 39
1 C8y C 15.7761 -17.5990
2 C8x C 15.7761 -18.9312
3 C8x C 16.8979 -19.5622
4 C8y C 18.0899 -18.9312
5 C8y C 18.0899 -17.5990
6 C8x C 16.8979 -16.8978
7 C1b C 19.2818 -16.8978
8 C8y C 20.4738 -17.5990
9 C8x C 20.4738 -18.9312
10 C8x C 21.5957 -19.5622
11 C8y C 22.7175 -18.9312
12 C8x C 22.7175 -17.5990
13 C8x C 21.5957 -16.8978
14 X Cl 19.2818 -19.5622
15 O2a O 23.9095 -19.5622
16 C1b C 25.0313 -18.9312
17 C1a C 26.1532 -19.5622
18 C1z C 14.5841 -16.8978
19 O2x O 14.5841 -15.5656
20 C1z C 13.3922 -14.8645
21 C1y C 12.2703 -15.5656
22 C1y C 12.2703 -16.8978
23 C1y C 13.3922 -17.5990
24 O1a O 13.3922 -18.9312
25 O1a O 11.0783 -14.8645
26 O1a O 11.0783 -17.5990
27 C1b C 13.3922 -13.5323
28 O1a O 14.5841 -12.8311
29 C1x C 14.8646 -14.0231
30 O2x O 16.2669 -15.9162
31 C5x C 29.7178 -15.4386
32 C1x C 30.1370 -16.7660
33 C1x C 31.5343 -16.7659
34 C1y C 32.0234 -15.5084
35 N1x N 30.9055 -14.6700
36 C6a C 33.2111 -14.7399
37 O6a O 34.3988 -15.4386
38 O6a O 33.2111 -13.3426
39 O5x O 28.3903 -15.0194
BOND 42
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 5 7 1
8 7 8 1
9 8 9 2
10 9 10 1
11 10 11 2
12 11 12 1
13 12 13 2
14 8 13 1
15 4 14 1
16 11 15 1
17 15 16 1
18 16 17 1
19 18 1 1 #Up
20 18 19 1
21 19 20 1
22 20 21 1
23 21 22 1
24 22 23 1
25 18 23 1
26 23 24 1 #Down
27 21 25 1 #Down
28 22 26 1 #Up
29 20 27 1 #Up
30 27 28 1
31 20 29 1 #Down
32 18 30 1 #Down
33 29 30 1
34 31 32 1
35 32 33 1
36 33 34 1
37 34 35 1
38 31 35 1
39 34 36 1 #Down
40 36 37 1
41 36 38 2
42 31 39 2
|
|---|
